Quarterly report [Sections 13 or 15(d)]

Statements of Operations (Unaudited)

v3.26.1
Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 383,724 $ 1,281,141
Selling, general and administrative (including related party amounts of $190,583 and $0, respectively) 1,542,658 1,058,662
Total operating expenses 1,926,382 2,339,803
Loss from operations (1,926,382) (2,339,803)
Other income and expenses:    
Interest income 78,676 36,216
Net loss $ (1,847,706) $ (2,303,587)
Net loss per share of Common Stock, basic $ (0.48) $ (4.47)
Net loss per share of Common Stock, diluted $ (0.48) $ (4.47)
Weighted-average basic Common Stock 3,858,921 515,465
Weighted-average diluted Common Stock 3,858,921 515,465